Authorities in the Democratic Republic of the Congo are shifting to a village-centered response as a fast-moving Ebola outbreak continues to outrun surveillance and treatment efforts. Government data cited Thursday by the Africa Centres for Disease Control and Prevention showed 6,250 confirmed cases and 3,039 deaths since the outbreak began in mid-May, across 60 health zones in six provinces.
Africa CDC said the outbreak, caused by Bundibugyo virus, probably has not peaked. Insecurity, displacement and intense population movement in eastern Congo are complicating the response, especially in Ituri, the epicentre. The World Health Organization said this week that Ituri accounted for 85% of cases and 88% of deaths, while mistrust and damaged infrastructure leave some communities difficult to reach.
The revised strategy puts local leaders and village health workers closer to detection, referral and public information. AP reported that at least 63% of deaths recorded in the latest week occurred outside Ebola treatment centres. Delayed reporting and deaths in the community raise the danger of transmission because the virus spreads through direct contact with the bodily fluids of sick people or those who have died.
Contact tracing remains a critical weakness. Surveillance teams followed 81% of people already listed as contacts, but Africa CDC estimated that recent cases should have generated about 97,600 contacts, based on an average of 60 per confirmed case. Only 19% of that expected total had been traced, indicating that many chains of transmission may remain invisible to responders.
Treatment and isolation capacity has expanded beyond 1,300 beds at 49 facilities, with 869 patients occupying about 67% of available places, according to health-agency figures. WHO said testing capacity had reached 3,000 samples a day through a network of 24 laboratories. It has also shipped more than 330 tonnes of emergency supplies and deployed more than 300 experts, but some centres remain saturated or inaccessible.
WHO and partners are testing treatments and possible vaccines because no licensed vaccine specifically targets Bundibugyo virus. Two candidate vaccines are in safety trials in Britain and Canada, while the licensed Zaire Ebola vaccine is being assessed for possible cross-protection. WHO plans efficacy trials in Congo in October or November and says the government-led six-month response requires $1.3 billion, making community trust, faster tracing and sustained financing central to containing the epidemic.
Comments